RobinC, BeckerichF, and CordonnierC: Immunization in cancer patients: Where we stand. Pharmacol Res, 2015; 92:23–30.
4.
ZhangL, ZhuF, XieL, WangC, WangJ, ChenR, JiaP, GuanHQ, PengL, ChenY, PengP, ZhangP, ChuQ, ShenQ, WangY, XuSY, ZhaoJP, and ZhouM: Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol, 2020; 31:894–901.
5.
OnderG, RezzaG, and BrusaferroS: Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA, 2020; 323:1775–1776.
6.
Al-QuteimatOM, and AmerAM: The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol, 2020; 43:452–455.
7.
BaşcıSA-O, AtaN, AltuntaşF, YiğenoğluTN, DalMS, KorkmazS, NamdaroğluS, BaştürkA, HacıbekiroğluT, DoğuMH, Berber İ, DalK, ErkurtMA, TurgutB, ÇelikO, ÜlgüMM, and Birinci Ş: Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Intern Emerg Med, 2021; 1–5.
HussainA, HasanA, Nejadi BabadaeiMM, BloukhSH, ChowdhuryMEH, SharifiM, HaghighatS, and M: Targeting SARS-CoV2 spike protein receptor binding domain by therapeutic antibodies. Biomed Pharmacother, 2020; 130:110559.
10.
SchiffmanK, RinnK, and DisisML: Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. Breast Cancer Res Treat, 2002; 74:17–23.
11.
LäubliHA-O, BalmelliC, KaufmannL, StanczakM, SyedbashaM, VogtD, HertigA, MüllerB, GautschiO, StennerF, ZippeliusA, EgliA, and RothschildSI: Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer, 2018; 6:40.
12.
ChongCR, ParkVJ, CohenB, PostowMA, WolchokJD, and KambojM: Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis, 2020; 70:193–199.
13.
LuoB, LiJ, HouX, YangQA-O, ZhouY, YeJ, WuX, FengY, HuT, XuZ, HeY, and SunJA-O: Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination. Future Oncol, 2021; 17:3477–3484.
14.
WatersAA-O, KepkaD, RamsayJM, MannK, Vaca LopezPL, AndersonJS, OuJY, KaddasHK, PalmerA, RayN, TsukamotoT, FairDB, LewisMA, KirchhoffAC, and WarnerEL: COVID-19 vaccine hesitancy among adolescent and young adult cancer survivors. JNCI Cancer Spectr, 2021; 5:pkab049.
15.
BetschCA-O, SchmidPA-O, HeinemeierDA-O, KornL, HoltmannC, and BöhmR: Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. PLoS One, 2018; 13:e0208601.
16.
MejriNA-O, BerrazegaY, OuertaniE, RachdiH, BohliM, KochbatiL, and BoussenH: Understanding COVID-19 vaccine hesitancy and resistance: Another challenge in cancer patients. Support Care Cancer, 2022; 30:289–293.
17.
Di NoiaV, RennaD, BarberiV, Di CivitaM, RivaF, CostantiniG, AquilaED, RussilloM, BraccoD, La MalfaAM, GiannarelliD, and CognettiF: The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey. Eur J Cancer, 2021; 153:260–264.
18.
LaneDA-O, NeelapuSA-O, XuGA-O, and WeaverOA-O: COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or prior breast cancer and other malignancies: Cross-sectional imaging findings on MRI, CT, and PET-CT. Korean J Radiol, 2021; 22:1938–1945.
19.
GarreffaE, HamadA, O'SullivanCC, HazimAZ, YorkJ, PuriS, TurnbullA, RobertsonJF, and GoetzMP: Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care. Eur J Cancer, 2021; 159:38–51.
20.
BurgerIA, Husmann L Fau - HanyTF, Hany Tf Fau - SchmidDT, Schmid Dt Fau - SchaeferNG, and SchaeferNG: Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine. Clin Nucl Med, 2011; 36:848–853.
21.
ShironeN, ShinkaiT, YamaneT, UtoF, YoshimuraH, TamaiH, ImaiT, InoueM, KitanoS, KichikawaK, and HasegawaM: Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination. Ann Nucl Med, 2012; 26:248–252.
22.
DanahyDB, BertonRR, and BadovinacVP: Cutting edge: Antitumor immunity by pathogen-specific CD8 T cells in the absence of cognate antigen recognition. J Immunol, 2020; 204:1431–1435.
23.
KimT-S, and ShinE-C: The activation of bystander CD8+ T cells and their roles in viral infection. Exp Mol Med, 2019; 51:1–9.
24.
MonjazebAM, TietzeJK, GrossenbacherSK, HsiaoHH, ZamoraAE, MirsoianA, KoehnB, BlazarBR, WeissJM, WiltroutRH, SckiselGD, and MurphyWJ: Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. PLoS One, 2014; 9:e102709.
25.
BernasconiNL, TraggiaiE, and LanzavecchiaA: Maintenance of serological memory by polyclonal activation of human memory B cells. Science, 2002; 298:2199–2202.
26.
KienleGS: Fever in cancer treatment: Coley's therapy and epidemiologic observations. Glob Adv Health Med, 2012; 1:92–100.
27.
NewmanJH, ChessonCB, HerzogNL, BommareddyPK, AspromonteSM, PepeR, EstupinianR, AboelattaMM, BuddhadevS, TarabichiS, LeeM, LiS, MedinaDJ, GiuriniEF, GuptaKH, Guevara-AlemanG, RossiM, NowickiC, AbedA, GoldufskyJW, BroucekJR, RedondoRE, RotterD, JhawarSR, WangSJ, KohlhappFJ, KaufmanHL, ThomasPA-O, GuptaV, KuzelTM, ReiserJ, ParasJ, KaneMP, SingerEA, MalhotraJ, DenzinLK, Sant'AngeloDB, RabsonAB, LeeLY, LasfarA, LangenfeldJ, SchenkelJM, FidlerMJ, RuizES, MarzoAL, RudraJS, SilkAW, and ZlozaA: Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. PNAS, 2020; 117:1119–1128.
